Evidence map›Paper›PMID 24900987›Full record

ArticleBioMed research international2014

Multidisciplinary management of hepatocellular carcinoma in clinical practice.

Gemma Bruera, Katia Cannita, Aldo Victor Giordano, Rosa Manetta, Roberto Vicentini, Sergio Carducci, Patrizia Saltarelli, Nerio Iapadre, Gino Coletti, Corrado Ficorella and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Sorafenib Plus Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023
    Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Gemma BrueraMedical Oncology, S. Salvatore Hospital, University of L'Aquila, 67100 L'Aquila, Italy ; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.ORCID 0000-0002-8407-2479
Katia CannitaMedical Oncology, S. Salvatore Hospital, University of L'Aquila, 67100 L'Aquila, Italy.
Aldo Victor GiordanoRadiology, S. Salvatore Hospital, 67100 L'Aquila, Italy.
Rosa ManettaRadiology, S. Salvatore Hospital, 67100 L'Aquila, Italy.
Roberto VicentiniHepatobiliar-Pancreatic Surgery, S. Salvatore Hospital, 67100 L'Aquila, Italy.
Sergio CarducciRadiology, S. Salvatore Hospital, 67100 L'Aquila, Italy.
Patrizia SaltarelliGastroenterology, S. Salvatore Hospital, 67100 L'Aquila, Italy.
Nerio IapadreInfective Disease, S. Salvatore Hospital, 67100 L'Aquila, Italy.
Gino ColettiPathology, S. Salvatore Hospital, 67100 L'Aquila, Italy.
Corrado FicorellaMedical Oncology, S. Salvatore Hospital, University of L'Aquila, 67100 L'Aquila, Italy ; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
Enrico RicevutoMedical Oncology, S. Salvatore Hospital, University of L'Aquila, 67100 L'Aquila, Italy ; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) patients require different treatment strategies according to disease extension, liver function, and patient's fitness. We evaluated HCC multidisciplinary management in clinical practice.

methodsConsecutive patients were followed and treated with tailored medical, locoregional, and surgical treatments, according to disease stage and patient's fitness (age, Cumulative Illness Rating Scale (CIRS)). Activity, efficacy, and safety were evaluated.

resultsThirty-eight patients were evaluated: median age, 74; elderly 92%; CIRS secondary 28 (74%); Child-Pugh A 20 (53%), B 11 (29%); and Barcelona Clinic Liver Cancer (BCLC) 0 2 (5%), A 9 (24%), B 10 (26%), C 13 (34%), and D 4 (11%). Overall survival (OS) was 30 months. At 9 months median follow-up, among 25 unresectable HCC, OS was 10 months; BCLC B-D unfit for sorafenib showed OS 3 months. Ten patients (40%) received sorafenib: Child-Pugh A 5 (50%) and B 5 (50%) and disease control rate 89%, progression-free survival 7 months, and OS 9 months. G3-4 toxicities: anorexia, hypertransaminaemia, hyperbilirubinemia, and hypercreatininemia. Limiting toxicity syndromes were 40%, all multiple sites.

conclusionHCC patients require multidisciplinary clinical management to properly select tailored treatments according to disease stage, fitness, and liver function. Patients suitable for sorafenib should be carefully selected, monitored for individual safety, and prevalently characterized by limiting toxicity syndromes multiple sites.

Indexed as

AgedAged, 80 and overAntineoplastic AgentsCarcinoma, HepatocellularDisease-Free SurvivalFemaleHumansLiver NeoplasmsMaleMiddle AgedNiacinamidePhenylurea CompoundsSeverity of Illness IndexSorafenibAntineoplastic AgentsNiacinamidePhenylurea CompoundsSorafenib

Identifiers

PMID24900987
PMCPMC4034404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.